Literature DB >> 9153413

Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells.

V Shanmugam1, I Chackalaparampil, G C Kundu, A B Mukherjee, B B Mukherjee.   

Abstract

It has been reported previously that oncogenically transformed cells secrete different molecular forms of osteopontin (OPN), a sialic acid-rich, adhesive, phosphoglycoprotein, than OPNs secreted by their nontransformed counterparts. However, the origin of the OPN isoform secreted by the transformed cells and whether it has different physiological properties which may serve transformation-specific functions remain poorly understood. Here, we report that Rat-1 cells transformed by a temperature-sensitive mutant of Rous sarcoma virus (tsB77) secrete two discrete molecular forms of OPN, a 69-kDa OPN at the nonpermissive temperature (41 degrees C) and a 62-kDa form at the permissive temperature (34 degrees C). However, tsB77 cells at both temperatures transcribe a single 1.6 kb OPN mRNA and contain only the 69-kDa form of OPN intracellularly, suggesting that the 69-kDa OPN is modified to the 62-kDa form prior to or immediately after secretion by cells at 34 degrees C. We ruled out proteolytic cleavage, differential phosphorylation, or lack of N- or O-linked carbohydrates as the possible mechanism, but found that the 62-kDa OPN contains significantly reduced levels of sialic acid, as compared to its 69-kDa form. The binding assays using 32P-labeled OPN revealed that only the 69-kDa OPN, not its 62-kDa form, undergoes receptor-mediated localization on the cell surface, although tsB77 cells synthesize OPN receptors (alpha(v)beta3 integrins) at both permissive and nonpermissive temperatures. Furthermore, 125I-labeled purified milk OPN, which is highly sialylated and shows cell surface binding, upon digestion with neuraminidase failed to interact with the cell surface. Taken together, these results suggest that the difference between the 69-kDa and 62-kDa isoforms of OPN resides in their sialic acid content, and sialylation of OPN is crucial for its receptor-mediated binding on tsB77 cells. The data presented here demonstrate for the first time a physiological role of sialic acids in this protein, and raise the possibility that oncogenically transformed tsB77 cells may exploit the lack of OPN-receptor interactions for their invasive behavior.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9153413     DOI: 10.1021/bi961687w

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  The effect of intracrystalline and surface-bound osteopontin on the degradation and dissolution of calcium oxalate dihydrate crystals in MDCKII cells.

Authors:  Lauren A Thurgood; Esben S Sørensen; Rosemary L Ryall
Journal:  Urol Res       Date:  2011-09-20

2.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

3.  The isolation and characterization of glycosylated phosphoproteins from herring fish bones.

Authors:  Hai-Yan Zhou; Erdjan Salih; Melvin J Glimcher
Journal:  J Biol Chem       Date:  2010-09-10       Impact factor: 5.157

4.  Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications.

Authors:  Brian Christensen; Mette S Nielsen; Kim F Haselmann; Torben E Petersen; Esben S Sørensen
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

Review 5.  Osteopontin: an effector and an effect of tumor metastasis.

Authors:  L A Shevde; S Das; D W Clark; R S Samant
Journal:  Curr Mol Med       Date:  2010-02       Impact factor: 2.222

6.  Nuclear factor inducing kinase: a key regulator in osteopontin- induced MAPK/IkappaB kinase dependent NF-kappaB-mediated promatrix metalloproteinase-9 activation.

Authors:  Hema Rangaswami; Anuradha Bulbule; Gopal C Kundu
Journal:  Glycoconj J       Date:  2006-05       Impact factor: 2.916

Review 7.  The role of osteopontin in breast cancer: clinical and experimental studies.

Authors:  A B Tuck; A F Chambers
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

8.  Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer.

Authors:  Farbod Shojaei; Nathan Scott; Xiaolin Kang; Patrick B Lappin; Amanda A Fitzgerald; Shannon Karlicek; Brett H Simmons; Aidong Wu; Joseph H Lee; Simon Bergqvist; Eugenia Kraynov
Journal:  J Exp Clin Cancer Res       Date:  2012-03-23

9.  Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma.

Authors:  Jules Lin; Amy L Myers; Zhuwen Wang; Derek J Nancarrow; Daysha Ferrer-Torres; Amy Handlogten; Kimmy Leverenz; Julia Bao; Dafydd G Thomas; Thomas D Wang; Mark B Orringer; Rishindra M Reddy; Andrew C Chang; David G Beer; Lin Lin
Journal:  Oncotarget       Date:  2015-09-08

10.  Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model.

Authors:  S Julien; G Picco; R Sewell; A-S Vercoutter-Edouart; M Tarp; D Miles; H Clausen; J Taylor-Papadimitriou; J M Burchell
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.